RESUMO
Background: Blood-related malignancies are the most common non-renal neoplasms affecting the kidneys. Renal involvementin patients with hematological malignancies varies according to the type of malignancy. The pathogenesis is either due to directinvolvement of the kidney or related to its treatment and/or effects of chemotherapy.Aim of the Study: This study aims to study and analyze the prevalence of kidney involvement in blood-related malignanciesand to observe the clinical and laboratory profile of patients in various hematological malignancies.Materials and Methods: A total of 93 consecutive patients of various hematological malignancies were included such asHodgkin’s disease, non-Hodgkin’s lymphoma, acute and chronic leukemias, and multiple myeloma. The renal involvement wasjudged on analysis of patient’s clinical parameters, urine analysis, biochemical, radiological, and when necessary, histologicalparameters. All the patients were investigated and treated on an established protocol described in literature. Patients wereadvised to give informed written consent followed by a detailed history taking and relevant physical examination. Patients wereasked about special emphasis on urinary symptoms and usage of nephrotoxic drugs.Observations and Results: A total of 93 consecutive patients of various hematological malignancies presenting to oncologyand medicine departments were included. There were 62 (66.66%) were male and 31 (33.33%) were female with a maleto-female ratio of 2:1. The youngest patient was aged 11 years and the eldest one was 81 years with a mean age of 43.13 ±16.2 years. Among 93 patients, 46/85 (49.46%) were diagnosed as leukemias, 27/93 (29.03%) patients had lymphomas, and20/93 (21.50%) patients were diagnosed as multiple myelomas. Acute leukemias were seen in 27/46 (58.69%) of the patientsand chronic leukemias in 19/46 (41.30%) of the patients. Forty-six patients with leukemias acute lymphatic leukemia were 7 inmales (25.92%) and 3 (11.11%) in females making it a total of 10/27 (37.03%), acute myeloid leukemia was 6 (22.22%) inmales and 3 (11.11%) in females with a total of 9/27 (33.33%). Acute basophilic leukemia was observed in 5 (18.51%) malepatients and 3 (11.11%) female patients; total 8/27 (29.62%). Chronic myeloid leukemia was seen in 5/19 (26.31%) male and2/19 (10.52%) female patients; 7/19 (36.84%).Conclusions: All patients with hematological malignancies should be periodically evaluated for renal dysfunction and necessarypreventive measures should be undertaken in such patients, especially when initiated on chemotherapy.
RESUMO
Objective Plasma circulating DNA can be em-ployed in place of bone marrow examination for the auxiliary diagnosis of leukemia.This study aimed to explore the clinical application of the plasma DNA level in evaluating the effect of chemotherapy on chronic leukemia. Methods We collected blood samples from 52 patients with chronic myelogenous leukemia (CML) (33 in the chronic phase, 7 in the acceleration phase, and 12 in the blast phase) , 85 with chron-ic lymphocytic leukemia (CLL) (28 with complete remission, 27 with partial remission, and 30 with no remission), 4 patients with hairy cell leukemia (HCL), and 80 healthy subjects.We simultaneously obtained plasma DNA and recombinant plasmid DNA using the BI-LATEST DNA Kit and examined the human β-actin gene and the level of plasmid DNA by real-time quantitative PCR. Results Before chemotherapy, the median value of plasma DNA was 149.46(30.63-496.91)ng/ml in the CML and 101.54(69.10-258.14) ng/ml in the CLL patients, both significantly higher than in the healthy controls (19.05[12.67-25.92]ng/ml) (P<0.01).After chemotherapy, the plasma DNA level of the CML patients was remarkably decreased, but still higher than that of the controls ( P<0.01).The CML patients in the chronic phase showed a markedly higher level of plasma DNA (302.89[93.33-541.52]ng/ml) than those in the blast phase (43.19[23.54-70.03]ng/ml) and acceleration phase (28.11[16.21-92.07]ng/ml) (P<0.05).The CLL patients with CR exhibited a significantly lower level of plasma DNA (24.29[14.64-30.74]ng/ml) than those with PR (106.88 [96.23-143.25]ng/ml) and NR (460.73[284.57-653.38〗ng/ml) (P<0.01), but all dramatically higher than that of the healthy controls (P<0.01) Conclusion The quantification of plasma DNA has a clinical application value in evaluating the effect of chemo-therapy on chronic leukemia.
RESUMO
88 patients with the chronic myeloid leukemia treated with Hydrea during 1/1999 - 12/2000. Most of them admitted to the center for hematology and blood transfusion in the conditions of very high leukocytosis and acute mortality risk due to cerebrovascular obstruction. Patients indicated by high dose of Hydrea in average duration of treatment of 6.5 (1.8 days. The treatment with Hydrea demonstrated that the survival duration of patients was lasted. The drug had fewer side effects. The treatment was not expensive. This is suitable for economic conditions of patients in Vietnam.
Assuntos
Leucemia Mielogênica Crônica BCR-ABL Positiva , TerapêuticaRESUMO
A patient with the chronic myeloid leukemia received the autologous stem cells transplantation of peripheral blood. The results have shown that the patient was responded well with the autograft, the graft grew early as estimation. The patient also responded completely with the treatment by Hydrea. The clinical and hematological signs were stable in the long-term. The complication during transplantation was mild. The total survival duration was 75 months.
Assuntos
Leucemia Mielogênica Crônica BCR-ABL Positiva , TerapêuticaRESUMO
A restrospective study carried out on 309 patients with chronic myelogenous leukemia treated from 1990 to 10/2000 showed that; -88 cases (28.3%) converted to the blast crisis. - 89.77% of these cases developed acute myeloblastic leukemia (AML) and 9.09% developed ALL.-The percentage of male and female were 55.68% and 44.31% - 45.45% of these converted cases occurred in the age group of 30-50. The youngest age was 10 months and the oldest age was : 72 years old. Mean of duration of the chronic phase was 2.5 years.